Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00621361 · ClinicalTrials.gov registry record · Phase 1
Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
NCT00621361 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 62 participants.
The verdict
NCT00621361, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
Study Summary
This study is to assess the safety and tolerability of Cediranib (RECENTIN™, AZD2171)in combination with etoposide and cisplatin (EP) as first line treatment for lung cancer patients with extensive stage or metastatic disease for whom EP would be a standard therapy.
Interventions
- DRUG Cisplatin
- DRUG Etoposide
- DRUG AZD2171
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2008-02 |
| Est. Completion | 2012-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00621361
The ClinicalTrials.gov registry entry for NCT00621361 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cisplatin is the first listed.
NCT00621361 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00621361 about?
NCT00621361 is a clinical study titled "Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients". This study is to assess the safety and tolerability of Cediranib (RECENTIN™, AZD2171)in combination with etoposide and cisplatin (EP) as first line treatment for lung cancer patients with extensive stage or metastatic disease for whom EP would be a standard therapy.
What is the current status of trial NCT00621361?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2008-02. Estimated completion is 2012-02.
What interventions are being tested in trial NCT00621361?
The interventions under investigation include: Cisplatin (DRUG), Etoposide (DRUG), AZD2171 (DRUG).
Who is sponsoring clinical trial NCT00621361?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.